Drugs / RAV12
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00101972 | Dec 2004 → May 2008 | cancer | MacroGenics | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00625586 | Apr 2008 → Jan 2009 | malignant pancreatic neoplasm | MacroGenics | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RAV12 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00625586 ↗ |
| Modality | Monoclonal antibody | “RAV12 is a high affinity, internalizing, chimeric IgG1 monoclonal antibody” PMID 20179219 ↗ Feb 2010 |
| Route | Intravenous | “Patients receive RAV12 IV over 2 hours 2-3 times per week in weeks 1-4 (course 1).” NCT00101972 ↗ |